RevMed pancreatic cancer drug approval and pricing
Revolution Medicines received US approval for Rasonque, a groundbreaking daily pill that extends survival in advanced pancreatic cancer patients by targeting the RAS protein mutation. Priced at over $475,000 annually, it represents one of the most expensive cancer treatments ever developed. The drug marks a significant therapeutic advance for pancreatic cancer, historically one of the most difficult cancers to treat.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending